UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.103

Sortiert nach

Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial

BMJ (Online), 2012-01, Vol.344 (7839), p.d7541

International edition, 2012

Link zum Volltext

Verfügbarkeit prüfen

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

The Lancet (British edition), 2005-09, Vol.366 (9489), p.895-906

2005

Link zum Volltext

Verfügbarkeit prüfen

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

The Lancet (British edition), 2003-11, Vol.362 (9395), p.1527-1535

Turnbull, Fiona

2003

Link zum Volltext

Verfügbarkeit prüfen

[LB.03.08] SERUM CHLORIDE AND ADVERSE CARDIOVASCULAR EVENTS IN THE ANGLO SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT)

Journal of hypertension, 2017-09, Vol.35 Suppl 2 - ESH 2017 Abstract Book (Supplement 2), p.e78-e79

2017

Link zum Volltext

Verfügbarkeit prüfen

DETERMINANTS OF LONG-TERM ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN HYPERTENSIVE PATIENTS – FINDINGS FROM 16-YEAR FOLLOW-UP OF THE ASCOT LEGACY STUDY

Journal of hypertension, 2018-06, Vol.36 Suppl 1 - ESH 2018 Abstract Book (Supplement 1), p.e27-e27

2018

Link zum Volltext

Verfügbarkeit prüfen

How common is true resistant hypertension?

Journal of human hypertension, 2011-02, Vol.25 (2), p.137-140

2011

Link zum Volltext

Verfügbarkeit prüfen

Tissue Doppler E/E′ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy

European heart journal, 2010-03, Vol.31 (6), p.747-752

2010

Link zum Volltext

Verfügbarkeit prüfen

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

European heart journal, 2006-12, Vol.27 (24), p.2982-2988

2006

Link zum Volltext

Verfügbarkeit prüfen

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure

European heart journal, 2008-02, Vol.29 (4), p.499-508

2008

Link zum Volltext

Verfügbarkeit prüfen

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials

The Lancet (British edition), 2000-12, Vol.356 (9246), p.1955-1964

2000

Link zum Volltext

Verfügbarkeit prüfen

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

The Lancet (British edition), 2005-09, Vol.366 (9489), p.907-913

2005

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)

Diabetes care, 2005-05, Vol.28 (5), p.1151-1157

2005

Link zum Volltext

Verfügbarkeit prüfen

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach

Diabetic medicine, 2011-08, Vol.28 (8), p.941-947

2011

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial

European heart journal, 2012-02, Vol.33 (4), p.486-494

2012

Link zum Volltext

Verfügbarkeit prüfen

[OP.1B.10] RISK SCORE FOR INCIDENT HEART FAILURE: A SUBJECT-LEVEL META-ANALYSIS FROM THE HEART ‘OMICS’ IN AGEING (HOMAGE) DATABASE

Journal of hypertension, 2016-09, Vol.34 Suppl 2 - ESH 2016 Abstract Book (Supplement 2), p.e7-e7

2016

Link zum Volltext

Verfügbarkeit prüfen

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

The Lancet (British edition), 2017-06, Vol.389 (10088), p.2473-2481

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

The Lancet (British edition), 2010-03, Vol.375 (9718), p.895-905

2010

Link zum Volltext

Verfügbarkeit prüfen

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial

International journal of clinical practice (Esher), 2010-08, Vol.64 (9), p.1228-1234

2010

Link zum Volltext

Verfügbarkeit prüfen

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data

Journal of human hypertension, 2013-08, Vol.27 (8), p.492-496

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

The Lancet (British edition), 2019-02, Vol.393 (10170), p.407-415

2019

Link zum Volltext

Verfügbarkeit prüfen

Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker

Journal of human hypertension, 1997-09, Vol.11 Suppl 2, p.S91

Sever, P

1997

Link zum Volltext

Verfügbarkeit prüfen

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

Lancet neurology, 2010-05, Vol.9 (5), p.469-480

2010

Link zum Volltext

Verfügbarkeit prüfen

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2264-2271

2015

Link zum Volltext

Verfügbarkeit prüfen

Baseline high sensitivity C-Reactive Protein predicts incident cardiovascular events and all-cause mortality in the ASCOT Study at 20-years

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Heart (British Cardiac Society), 2008-02, Vol.94 (2), p.e4-e4

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.002)
Mit Volltextzugriff
(928)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(682)
Humans
(514)
Life Sciences & Biomedicine
(503)
Female
(297)
Male
(276)
Biological And Medical Sciences
(232)
Medical Sciences
(205)
Adult
(195)
Middle Aged
(192)
Cardiovascular System & Cardiology
(147)
Aged
(142)
Physical Sciences
(133)
Hypertension - Drug Therapy
(101)
General & Internal Medicine
(100)
Medicine, General & Internal
(98)
Hypertension
(95)
Animals
(94)
Blood Pressure
(92)
Peripheral Vascular Disease
(92)
Physics
(82)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Lancet
(63)
Journal Of Hypertension
(59)
Journal Of Human Hypertension
(44)
Physics Letters. B
(42)
Bmj
(24)
American Journal Of Hypertension
(23)
Journal Of Cardiovascular Pharmacology
(19)
Nuclear Physics. B
(19)
British Medical Journal
(18)
Circulation
(17)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

[LB.03.08] SERUM CHLORIDE AND ADVERSE CARDIOVASCULAR EVENTS IN THE ANGLO SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT)

DETERMINANTS OF LONG-TERM ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN HYPERTENSIVE PATIENTS – FINDINGS FROM 16-YEAR FOLLOW-UP OF THE ASCOT LEGACY STUDY

How common is true resistant hypertension?

Tissue Doppler E/E′ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial

[OP.1B.10] RISK SCORE FOR INCIDENT HEART FAILURE: A SUBJECT-LEVEL META-ANALYSIS FROM THE HEART ‘OMICS’ IN AGEING (HOMAGE) DATABASE

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Baseline high sensitivity C-Reactive Protein predicts incident cardiovascular events and all-cause mortality in the ASCOT Study at 20-years

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Suchergebnisse filtern